This is a news story, published by Yahoo Finance, that relates primarily to Casgevy news.
For more Casgevy news, you can click here:
more Casgevy newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
CRISPR Therapeutics. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest biotech stock trades news, top pharmaceutical stock news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cheap healthcare stocksThe Motley Fool
•73% Informative
CRISPR Therapeutics' market cap is $4.2 billion despite the recent approval of Casgevy , a treatment for two blood-related diseases it developed in collaboration with Vertex Pharmaceuticals .
Gilead Sciences recently announced that lenacapavir, its twice-yearly HIV treatment, was highly effective in preventing HIV infections by 96% in a phase 3 trial.
Pfizer has been a big loser in recent years although it has eked out a meager gain in 2024 .
Pfizer 's shares trade at only 10.6 times forward earnings.
The company has invested in developing new products, with respiratory syncytial virus ( RSV ) vaccine Abrysvo especially standing out.
Pfizer should be able to deliver solid growth in the coming years despite losing patent exclusivity for multiple products.
VR Score
67
Informative language
65
Neutral language
17
Article tone
formal
Language
English
Language complexity
44
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
9
Source diversity
2
Affiliate links
no affiliate links